• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    11/16/23 12:31:00 PM ET
    $APYX
    $AUGX
    $BBLG
    $DRMA
    Medical/Dental Instruments
    Health Care
    Business Services
    Consumer Discretionary
    Get the next $APYX alert in real time by email

    Gainers

    • LumiraDx (NASDAQ:LMDX) shares rose 42.8% to $0.14 during Thursday's regular session. LumiraDx's stock is trading at a volume of 62.6 million shares as of 12:30 EST. This is 685.7% of its average full-day volume over the last 100 days. The company's market cap stands at $45.0 million.
    • Bone Biologics (NASDAQ:BBLG) stock rose 26.55% to $0.69. Bone Biologics's stock is trading at a volume of 39.5 million shares as of 12:30 EST. This is 11857.4% of its average full-day volume over the last 100 days. The company's market cap stands at $2.1 million. As per the news, the Q3 earnings report came out 2 days ago.
    • Impel Pharmaceuticals (NASDAQ:IMPL) shares moved upwards by 25.04% to $0.35. As of 12:30 EST, this security is trading at a volume of 10.5 million shares, making up 1154.2% of its average full-day volume over the last 100 days. The company's market cap stands at $8.3 million.
    • Iterum Therapeutics (NASDAQ:ITRM) stock moved upwards by 23.42% to $1.08. As of 12:30 EST, Iterum Therapeutics's stock is trading at a volume of 527.7K, which is 1579.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $14.0 million. As per the press release, Q3 earnings came out 2 days ago.
    • Apyx Medical (NASDAQ:APYX) shares rose 20.13% to $1.79. Apyx Medical's stock is trading at a volume of 323.0K shares as of 12:30 EST. This is 235.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $62.0 million.
    • Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 18.11% to $0.77. Dermata Therapeutics's stock is trading at a volume of 7.7 million shares as of 12:30 EST. This is 6271.2% of its average full-day volume over the last 100 days. The company's market cap stands at $2.4 million.

    Losers

    • Homology Medicines (NASDAQ:FIXX) stock decreased by 39.9% to $0.53 during Thursday's regular session. As of 12:30 EST, Homology Medicines's stock is trading at a volume of 5.7 million, which is 3300.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $30.5 million. As per the news, the Q3 earnings report came out 2 days ago.
    • MEI Pharma (NASDAQ:MEIP) shares decreased by 23.57% to $5.99. MEI Pharma's stock is trading at a volume of 141.1K shares as of 12:30 EST. This is 299.8% of its average full-day volume over the last 100 days. The company's market cap stands at $39.9 million.
    • Augmedix (NASDAQ:AUGX) shares fell 20.45% to $4.32. The current volume of 2.5 million shares is 1128.7% of Augmedix's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $176.2 million.
    • SAB Biotherapeutics (NASDAQ:SABS) shares decreased by 16.81% to $0.76. The current volume of 140.6K shares is 286.7% of SAB Biotherapeutics's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $39.6 million. The company's, Q3 earnings came out 3 days ago.
    • PaxMedica (NASDAQ:PXMD) shares decreased by 15.3% to $2.05. PaxMedica's stock is trading at a volume of 494.0K shares as of 12:30 EST. This is 49.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.2 million.
    • Syra Health (NASDAQ:SYRA) shares decreased by 15.07% to $1.24. The market value of their outstanding shares is at $1.0 million. The company's, Q3 earnings came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APYX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APYX
    $AUGX
    $BBLG
    $DRMA

    CompanyDatePrice TargetRatingAnalyst
    SAB Biotherapeutics Inc.
    $SABS
    12/19/2025$15.00Buy
    Guggenheim
    Apyx Medical Corporation
    $APYX
    12/16/2025$6.00Buy
    Roth Capital
    Apyx Medical Corporation
    $APYX
    11/14/2025Mkt Perform → Mkt Outperform
    Citizens JMP
    Apyx Medical Corporation
    $APYX
    11/12/2025$8.00Mkt Perform → Mkt Outperform
    Citizens JMP
    SAB Biotherapeutics Inc.
    $SABS
    9/17/2025$7.00Outperform
    Leerink Partners
    SAB Biotherapeutics Inc.
    $SABS
    5/14/2025$10.00Buy
    H.C. Wainwright
    Apyx Medical Corporation
    $APYX
    10/17/2024Neutral
    BTIG Research
    SAB Biotherapeutics Inc.
    $SABS
    10/9/2024$11.00Buy
    Craig Hallum
    More analyst ratings

    $APYX
    $AUGX
    $BBLG
    $DRMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dunne Michael W. bought $2,191 worth of Ordinary Shares (6,000 units at $0.37), increasing direct ownership by 3% to 241,001 units (SEC Form 4)

    4 - Iterum Therapeutics plc (0001659323) (Issuer)

    11/20/25 7:00:04 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dunne Michael W. bought $10,854 worth of Ordinary Shares (15,000 units at $0.72), increasing direct ownership by 7% to 235,001 units (SEC Form 4)

    4 - Iterum Therapeutics plc (0001659323) (Issuer)

    8/12/25 7:00:06 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Chief Financial Officer Hill Matthew C bought $6,780 worth of shares (6,000 units at $1.13), increasing direct ownership by 240% to 8,500 units (SEC Form 4)

    4/A - Apyx Medical Corp (0000719135) (Issuer)

    3/3/25 4:05:12 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    $APYX
    $AUGX
    $BBLG
    $DRMA
    SEC Filings

    View All

    SEC Form 10-K filed by Apyx Medical Corporation

    10-K - Apyx Medical Corp (0000719135) (Filer)

    3/10/26 1:11:10 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    SAB Biotherapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)

    3/10/26 7:35:30 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apyx Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Apyx Medical Corp (0000719135) (Filer)

    3/10/26 7:01:32 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    $APYX
    $AUGX
    $BBLG
    $DRMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by PRESIDENT Sullivan Eddie Joe

    4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

    2/5/26 4:55:03 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by CEO Reich Samuel J

    4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

    2/5/26 4:50:05 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by CHIEF OPERATING OFFICER Bausch Christoph Lawrence

    4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

    2/5/26 4:45:03 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APYX
    $AUGX
    $BBLG
    $DRMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on SAB BIO with a new price target

    Guggenheim initiated coverage of SAB BIO with a rating of Buy and set a new price target of $15.00

    12/19/25 8:51:08 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Roth Capital initiated coverage on Apyx Medical with a new price target

    Roth Capital initiated coverage of Apyx Medical with a rating of Buy and set a new price target of $6.00

    12/16/25 8:46:26 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Apyx Medical upgraded by Citizens JMP

    Citizens JMP upgraded Apyx Medical from Mkt Perform to Mkt Outperform

    11/14/25 10:23:10 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    $APYX
    $AUGX
    $BBLG
    $DRMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $APYX
    $AUGX
    $BBLG
    $DRMA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

    Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced additional data from the Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of SAB-142. The established T1D adult patient cohort demonstrated early signals of C-peptide preservation which aligned with the anticipated mechanism of action o

    3/10/26 7:31:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

    Reported record total revenue of $19.2 million in the fourth quarter of 2025Scaling U.S. commercial launch of AYON Body Contouring System™ (AYON) to meet strong market demandExpect FY2026 total revenue in the range of $57.5 million to $58.5 millionManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its fourth quarter and full year ended December 31, 2025. Recent Financial and Operating Highlights: Reported

    3/10/26 7:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

    Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027 Reported Phase 1 clinical data, including healthy volunteer, redosing, and T1D cohorts supporting SAB-142's favorable safety profile, redosability, and continued clinical development Raised $175 million in an oversubscribed private placement with leading institutional and strategic investors to fully fund SAFEGUARD Strong cash position with operational runway through 2028 MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutica

    3/9/26 5:16:37 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APYX
    $AUGX
    $BBLG
    $DRMA
    Financials

    Live finance-specific insights

    View All

    Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

    Reported record total revenue of $19.2 million in the fourth quarter of 2025Scaling U.S. commercial launch of AYON Body Contouring System™ (AYON) to meet strong market demandExpect FY2026 total revenue in the range of $57.5 million to $58.5 millionManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its fourth quarter and full year ended December 31, 2025. Recent Financial and Operating Highlights: Reported

    3/10/26 7:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Apyx Medical Corporation to Release Fourth Quarter of Fiscal Year 2025 Financial Results on March 10, 2026

    CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the fourth quarter of fiscal year 2025 will be released before markets open on Tuesday, March 10th. Management will host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 10th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81

    2/25/26 9:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Iterum Therapeutics Reports Third Quarter 2025 Financial Results

    --Commercially Launched ORLYNVAH™ in the United States in August 2025-- --Extended Cash Runway into Q2 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended September 30, 2025. "We are thrilled to have launched ORLYNVAH™ in the United States in August 2025 for the treatment of uncomplicated urinary tract infections (uUTIs)," said

    11/14/25 7:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APYX
    $AUGX
    $BBLG
    $DRMA
    Leadership Updates

    Live Leadership Updates

    View All

    SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

    David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D. to its Board of Directors as Chair of the Board and the appointment of Rita Jain, M.D., as an independent director, both effective immediately. "We are excited to welcome Dr. David Zaccardelli and Dr. Rita Jain to our Board of Directors. I, along with the rest of our Board, am confi

    1/7/26 8:00:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Syra Health Appoints Healthcare Executive and Former U.S. Marine Gregory R. Alexander as Chief Executive Officer to Drive Growth

    Proven C-Suite Leader with Track Record of Scaling Healthcare Organizations Joins Syra Health to Accelerate Market Expansion and Industry Impact CARMEL, Ind., Dec. 18, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare solutions company dedicated to powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today the appointment of Gregory R. Alexander as Chief Executive Officer, effective January 5, 2026. Alexander's career has been defined by consistently driving growth and excee

    12/18/25 8:55:00 AM ET
    $SYRA
    Diversified Commercial Services
    Consumer Discretionary

    Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth

    DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer. In this role, Ms. Coyne will lead all commercial efforts for Iterum, including the upcoming launch of ORLYNVAH™ in the United States, as well as future commercialization activities across new products and markets. "We are delighted to welcome Christine to the Iterum leadership team at such a pivotal time for the company," said

    6/30/25 7:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APYX
    $AUGX
    $BBLG
    $DRMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Iterum Therapeutics plc

    SC 13G/A - Iterum Therapeutics plc (0001659323) (Subject)

    11/14/24 7:54:21 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/14/24 7:19:34 PM ET
    $BBLG
    Industrial Specialties
    Health Care